Info

🌱 來自: alectinib

ALK

ALK ASCO recommendation

ALK fusion

• 4% of ADCL,
• a/w younger males,
• never-smoking hx,
• various ALK fusion partners (EML4-ALK most common),
• Sn to ALK kinase inhibitors (NEJM 2010;363:1693)

treatment

• Initial tx:
  • Alectinib (ORR 83%, PFS 34.8 mos) (NEJM 2017;377:829),
  • brigatinib (ORR 74%, PFS 24.0 mos),
  • ceritinib,
  • or lorlatinib (ORR 76%)
• Subsequent tx:
  • Lorlatinib if previously treated w/ alectinib or brigatinib;
  • consider alectinib, ceritinib, or brigatinib if previously treated w/ crizotinib. Rebiopsy may guide agent choice based on resistance mts

Slides

• ALKi in NSCLC

Backlink

• non-small cell lung cancers
• mechanisms and sites of action of some of the drugs used in the treatment of cancer
• inpatient oncology
• alectinib
• WHO Classification of Lymphoid Malignancies
• Oncology - Inpatient Oncology - Fast Facts NEJM Resident 360
• NSCLC
• NSCLC Treatment
• Molecular biology-of-NSCLC
• Genetics of Diagnostic and staging evaluation of lung cancer
• Autoimmune Etiologies of Liver Disease
• Adeno or Other in Stage IV NSCLC Treatment